Neurocritical Care News

PHILADELPHIA — To effectively address symptoms of dementia with Lewy bodies, the medical community must address obstacles such as accurate diagnosis, lack of treatment options and dearth of clinical trials, according to a presenter.

PHILADELPHIA — A hypertension diagnosis in those who suffered a concussion was linked to longer recovery periods compared to those without, and was associated with likelihood of post-concussion syndrome, according to a poster presentation.

The FDA has granted 510(k) clearance to a radiology artificial intelligence firm for triage and notification of obstructive hydrocephalus on non-contrast brain CT scans, according to a release.

PHILADELPHIA — Safe and effective ways to introduce anti-amyloid medications for Alzheimer’s disease depends on comprehensive care infrastructure from screening to administration, according to a speaker.

PHILADELPHIA — Older adults who sustained a prior head injury were nearly two times as likely to sustain a future fall compared with those who did not have a prior head injury, according to a poster presentation.

PHILADELPHIA — A genetic risk test for patients with multiple sclerosis can identify drugs that may lead to development of progressive multifocal leukoencephalopathy, per data presented at the American Neurological Association annual meeting.

PHILADELPHIA — Many patients with mild traumatic brain injury have central sensitization, a pain that requires a different therapeutic approach than nociceptic pain, according to a study by Christopher File, BSA, and colleagues.

PHILADELPHIA — Better sleep boosts quality of life and may have positive long-reaching benefits including reduction of risk for neurological disorders, according to research presented at the American Neurological Association annual meeting.

A single dose of psilocybin resulted in clinically and statistically significant reductions in depressive symptoms and functional disability compared with placebo in patients with major depressive disorder, according to a phase 2 study.

A global clinical-stage specialty biopharmaceutical company has announced positive topline results from its study of its investigational therapeutic AM0-02 to treat children and adolescents with congenital myotonic dystrophy.